How Better Business Development Fuels Medtech M&A

Posted by Tobi Laczkowski on December 16, 2019

As we discussed in a previous post, medtech companies are increasingly using M&A to accelerate growth, complement product portfolios and add talented personnel. In addition to the traditional role of business development as the execution arm of upstream strategy, we’ve seen some of the best business development groups take on a broader mandate, which extends their impact further upstream and coordinates more closely with traditional marketing functions. With that vision, the business development group obtains a solid grasp of market trends, unmet customer needs and emerging companies of interest. To do so, the business development group should work closely with commercial leaders to align on objectives, strategy and opportunity identification. Additionally, the group needs to coordinate with R&D leadership to align on investments and initiatives which complement potential external opportunities.


>
Read More

What More M&A Means for Medtech

Posted by Tobi Laczkowski on December 11, 2019

Mergers and acquisitions (M&A) is a hot topic in the medtech industry. Stryker recently announced a planned acquisition of Wright Medical for approximately $5 billion, which will bolster its orthopedic portfolio and transform it into the upper echelon of leadership within the category. This follows a trend that we’re tracking closely as the industry continues to evolve.  


>
Read More

Ushering in 2019: Medtech’s Year to Come

Posted by Tobi Laczkowski on January 17, 2019

A new year has come, so it’s time to take a step back and make some observations about the industry’s 2018 evolution and provide some thoughts on how 2019 is shaping up.


>
Read More

A View From the Other Side: Four Lessons for Medtech Startups From OutcomeMD

Posted by Tobi Laczkowski on May 23, 2018

Maurice Solomon co-wrote this blog post with Tobi Laczkowski.

We recently published a Q&A with Tim Schmid, the chief strategic customer officer at the Johnson & Johnson Medical Devices Companies. He provided an excellent overview of the changing healthcare market, and how J&J and other large medtech companies are pivoting along with it. 


>
Read More

Threading the Needle: Post-Merger Communication and Compensation Plans

Posted by Tobi Laczkowski on November 29, 2017

For many medtech companies, the end of the calendar year is also the end of the fiscal year—a critical period of transition as management teams prepare organizational design strategies for the following year. Organizations in the midst of integration mergers and other transitions can expect even bigger changes during this time than in “normal” years. They need to thread the needle between over-communicating and under-communicating during this period of uncertainty while balancing the inherent challenges of creating a combined organization with unified values, processes and goals. With that in mind, management teams face a fundamental dilemma: How best to communicate what sales teams can expect in the next year without disrupting necessary end-of-year activities.


>
Read More